Eyepoint Gross Profit from 2010 to 2024

EYPT Stock

USD 8.95 0.60 7.19%

Eyepoint Pharmaceuticals Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Eyepoint Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2002-09-30

Previous Quarter

8.1 M

Current Value

9.8 M

Quarterly Volatility

5 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 440.8 K, Interest Expense of 1.6 M or Total Revenue of 48.3 M, as well as many indicators such as Price To Sales Ratio of 18.09, Dividend Yield of 0.0 or PTB Ratio of 3.13. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Latest Eyepoint Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Eyepoint Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Eyepoint Pharmaceuticals minus its cost of goods sold. It is profit before Eyepoint Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Eyepoint Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 26.95 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Eyepoint Gross Profit Regression Statistics

	Arithmetic Mean	13,605,575
	Geometric Mean	9,423,061
	Coefficient Of Variation	138.44
	Mean Deviation	16,573,104
	Median	7,539,000
	Standard Deviation	18,836,129
	Sample Variance	354.8T
	Range	59M
	R-Value	0.79
	Mean Square Error	144.7T
	R-Squared	0.62
	Significance	0.0005
	Slope	3,320,017
	Total Sum of Squares	4967.2T

Eyepoint Gross Profit History

	2024	43.5 M
	2023	41.4 M
	2022	33.1 M
	2021	28.8 M
	2020	28.6 M
	2019	17.7 M
	2018	-15.5 M

Other Fundumenentals of Eyepoint Pharmaceuticals

Gross Profit Margin

Eyepoint Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Short Term Investments	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Long Term Debt Total	Short Long Term Debt	Capital Stock
Total Assets		0.98	-0.95	-0.88	0.32	0.85	1.0	0.51	0.0	0.62	0.83	-0.21	0.67	-0.23	0.89	0.87	0.79	0.4	0.99	0.99	0.61	-0.73	-0.77
Total Stockholder Equity	0.98		-0.98	-0.79	0.19	0.72	0.99	0.35	-0.13	0.47	0.79	-0.16	0.53	-0.19	0.9	0.88	0.7	0.28	0.97	0.99	0.48	-0.58	-0.68
Net Debt	-0.95	-0.98		0.73	-0.03	-0.66	-0.96	-0.28	0.27	-0.39	-0.7	0.13	-0.45	0.16	-0.85	-0.82	-0.64	-0.23	-0.94	-0.96	-0.39	0.53	0.61
Retained Earnings	-0.88	-0.79	0.73		-0.5	-0.92	-0.86	-0.62	-0.29	-0.74	-0.75	0.51	-0.8	0.53	-0.78	-0.7	-0.86	-0.6	-0.86	-0.84	-0.73	0.84	0.81
Net Receivables	0.32	0.19	-0.03	-0.5		0.59	0.28	0.55	0.84	0.62	0.68	-0.18	0.67	-0.18	0.29	0.44	0.63	0.46	0.35	0.3	0.7	-0.61	-0.61
Total Liab	0.85	0.72	-0.66	-0.92	0.59		0.81	0.81	0.34	0.87	0.75	-0.29	0.89	-0.3	0.68	0.66	0.85	0.63	0.84	0.8	0.81	-0.97	-0.83
Total Current Assets	1.0	0.99	-0.96	-0.86	0.28	0.81		0.43	-0.04	0.56	0.82	-0.19	0.63	-0.21	0.91	0.88	0.77	0.36	0.99	1.0	0.56	-0.68	-0.75
Intangible Assets	0.51	0.35	-0.28	-0.62	0.55	0.81	0.43		0.44	0.82	0.46	-0.27	0.74	-0.28	0.3	0.32	0.6	0.57	0.49	0.43	0.68	-0.87	-0.53
Common Stock	0.0	-0.13	0.27	-0.29	0.84	0.34	-0.04	0.44		0.4	0.4	-0.35	0.4	-0.34	0.04	0.16	0.41	0.41	0.02	-0.03	0.37	-0.39	-0.37
Accounts Payable	0.62	0.47	-0.39	-0.74	0.62	0.87	0.56	0.82	0.4		0.55	-0.25	0.92	-0.26	0.39	0.41	0.69	0.66	0.63	0.56	0.88	-0.92	-0.52
Property Plant Equipment	0.83	0.79	-0.7	-0.75	0.68	0.75	0.82	0.46	0.4	0.55		-0.16	0.62	-0.18	0.79	0.94	0.82	0.38	0.85	0.84	0.58	-0.66	-0.81
Current Deferred Revenue	-0.21	-0.16	0.13	0.51	-0.18	-0.29	-0.19	-0.27	-0.35	-0.25	-0.16		-0.22	1.0	-0.18	-0.12	-0.24	-0.28	-0.17	-0.16	-0.2	0.24	0.18
Long Term Debt	0.67	0.53	-0.45	-0.8	0.67	0.89	0.63	0.74	0.4	0.92	0.62	-0.22		-0.23	0.43	0.43	0.76	0.79	0.69	0.63	0.94	-0.91	-0.71
Short Term Debt	-0.23	-0.19	0.16	0.53	-0.18	-0.3	-0.21	-0.28	-0.34	-0.26	-0.18	1.0	-0.23		-0.2	-0.13	-0.25	-0.29	-0.19	-0.18	-0.21	0.26	0.19
Short Term Investments	0.89	0.9	-0.85	-0.78	0.29	0.68	0.91	0.3	0.04	0.39	0.79	-0.18	0.43	-0.2		0.89	0.72	0.16	0.88	0.9	0.38	-0.52	-0.68
Net Tangible Assets	0.87	0.88	-0.82	-0.7	0.44	0.66	0.88	0.32	0.16	0.41	0.94	-0.12	0.43	-0.13	0.89		0.73	0.19	0.88	0.89	0.39	-0.54	-0.7
Capital Surpluse	0.79	0.7	-0.64	-0.86	0.63	0.85	0.77	0.6	0.41	0.69	0.82	-0.24	0.76	-0.25	0.72	0.73		0.65	0.8	0.77	0.67	-0.84	-0.78
Deferred Long Term Liab	0.4	0.28	-0.23	-0.6	0.46	0.63	0.36	0.57	0.41	0.66	0.38	-0.28	0.79	-0.29	0.16	0.19	0.65		0.44	0.38	0.58	-0.71	-0.47
Net Invested Capital	0.99	0.97	-0.94	-0.86	0.35	0.84	0.99	0.49	0.02	0.63	0.85	-0.17	0.69	-0.19	0.88	0.88	0.8	0.44		1.0	0.61	-0.73	-0.76
Net Working Capital	0.99	0.99	-0.96	-0.84	0.3	0.8	1.0	0.43	-0.03	0.56	0.84	-0.16	0.63	-0.18	0.9	0.89	0.77	0.38	1.0		0.57	-0.68	-0.75
Long Term Debt Total	0.61	0.48	-0.39	-0.73	0.7	0.81	0.56	0.68	0.37	0.88	0.58	-0.2	0.94	-0.21	0.38	0.39	0.67	0.58	0.61	0.57		-0.82	-0.66
Short Long Term Debt	-0.73	-0.58	0.53	0.84	-0.61	-0.97	-0.68	-0.87	-0.39	-0.92	-0.66	0.24	-0.91	0.26	-0.52	-0.54	-0.84	-0.71	-0.73	-0.68	-0.82		0.74
Capital Stock	-0.77	-0.68	0.61	0.81	-0.61	-0.83	-0.75	-0.53	-0.37	-0.52	-0.81	0.18	-0.71	0.19	-0.68	-0.7	-0.78	-0.47	-0.76	-0.75	-0.66	0.74

Click cells to compare fundamentals

About Eyepoint Pharmaceuticals Financial Statements

Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	41.4 M	43.5 M
Gross Profit Margin	0.90	0.94

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC